Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Clin Nutr. 2018 Dec;37(6 Pt A):1840-1851. doi: 10.1016/j.clnu.2017.09.011. Epub 2017 Sep 23.
BACKGROUND & AIMS: Duchenne Muscular Dystrophy (DMD) is the most frequent dystrophy in childhood generated by a deficiency in dystrophin. DMD is a neuromuscular disease and its clinical course comprises chronic inflammation and gradual muscle weakness. Supplementation of omega-3 long chain-Polyunsaturated Fatty Acids (ω-3 long chain-PUFA) reduces inflammatory markers in various disorders. The goal of this research was to analyze the influence of ω-3 long chain-PUFA intake on gene expression and blood inflammatory markers in boys with DMD.
In a placebo-controlled, double. Blind, randomized trial, boys with DMD (n = 36) consumed 2.9 g/day of ω-3 long chain-PUFA or sunflower oil as control, in capsules, for a period of 6 months. Blood was analyzed at baseline and at months 1, 2, 3, and 6 of supplementation for expression of inflammatory markers in leukocytes and serum.
There was high adherence to capsule intake (control: 95.3% ± 7.2%, and ω-3 long chain-PUFA: 97.4% ± 3.7% at month 6). Enrichment of EicosaPentaenoic Acid (EPA) and DocosaHexaenoic Acid (DHA) in erythrocytes increased significantly in patients supplemented with ω-3 long chain-PUFA compared with the placebo group during the 6 months of supplementation. Messenger RNA (mRNA) of the Nuclear Factor kappa beta (NF-κB) and its target genes InterLeukin 1 beta (IL-1β) and IL-6 was downregulated significantly (p < 0.05) in leukocytes from DMD boys supplemented with ω-3 long chain-PUFA for 6 months, compared to the placebo group. Omega-3 long chain-PUFA intake decreased the serum IL-1β (-59.5%; p = 0.011) and IL-6 (-54.8%; p = 0.041), and increased the serum IL-10 (99.9%, p < 0.005), in relation to those with placebo treatment.
Supplementation with ω-3 long chain-PUFA 2.9 g/day is well-tolerated, has a beneficial reductive effect on proinflammatory markers, and increases an anti-inflammatory marker, indicating that ω-3 long chain-PUFA could have a potential therapeutic impact on chronic inflammation in DMD. This research is registered at clinicaltrials.gov (NCT018264229).
杜氏肌营养不良症（DMD）是儿童中最常见的肌营养不良症，由肌营养不良蛋白缺乏引起。DMD 是一种神经肌肉疾病，其临床过程包括慢性炎症和逐渐的肌肉无力。ω-3 长链多不饱和脂肪酸（ω-3 LCPUFA）的补充可降低各种疾病中的炎症标志物。本研究旨在分析 DMD 男孩摄入 ω-3 LCPUFA 对基因表达和血液炎症标志物的影响。
在一项安慰剂对照、双盲、随机试验中，36 名 DMD 男孩（n=36）每天服用 2.9g ω-3 LCPUFA 或葵花籽油作为对照，胶囊形式，持续 6 个月。在补充的第 1、2、3、6 个月时，分析血液白细胞和血清中炎症标志物的表达。
胶囊摄入量的依从性很高（对照组：95.3%±7.2%，ω-3 LCPUFA 组：97.4%±3.7%，第 6 个月）。与安慰剂组相比，ω-3 LCPUFA 组患者的红细胞中二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的富集在 6 个月的补充期间显著增加。与安慰剂组相比，DMD 男孩服用 ω-3 LCPUFA 6 个月后，白细胞核因子 kappa B（NF-κB）及其靶基因白细胞介素 1β（IL-1β）和白细胞介素 6（IL-6）的信使 RNA（mRNA）显著下调（p<0.05）。与安慰剂治疗相比，ω-3 LCPUFA 摄入可降低血清白细胞介素 1β（-59.5%；p=0.011）和白细胞介素 6（-54.8%；p=0.041），增加血清白细胞介素 10（99.9%，p<0.005）。
每天补充 2.9g ω-3 LCPUFA 耐受性良好，对促炎标志物具有有益的降低作用，并增加抗炎标志物，表明 ω-3 LCPUFA 可能对 DMD 的慢性炎症具有潜在的治疗作用。本研究在 clinicaltrials.gov（NCT018264229）注册。
